Endpoints News – The biopharma world is here

SUBSCRIBE

top stories

A new study points to $6.5B in public support building the scientific foundation of Gilead's remdesivir. Should that be reflected in the price?

15 hours ago

UPDATED: Biogen shares spike as execs complete a delayed pitch for their controversial Alzheimer's drug — the next ...

22 hours ago

Merck dangles up to $425 million to team with Flagship’s Foghorn Therapeutics on drugging the shape of DNA

22 hours ago

Latest

Most read

OWS shifts spotlight to drugs to fight Covid-19, handing Regeneron $450M to begin large scale manufacturing in the US

Yesterday

Covid-19 roundup: After promising US its summer supply, Gilead in talks with EU over remdesivir access; First inhaled ...

Just now

Zai Lab inks China deal with Turning Point with $25M upfront; Xencor, Atreca team up on bispecifics

19 hours ago

Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs

19 hours ago

see latest stream

People

Tesla chief Elon Musk teams up with Covid-19 player CureVac to build 'RNA microfactories'

6 days ago

Regeneron co-founder George Yancopoulos offers a combative defense of the police at a high school commencement. It ...

Last week

Elias Zerhouni discusses ‘amateur hour’ in DC, the destruction of infectious disease R&D and how we need to prep ...

Last week

Startups

Flagship execs take a lesson from nature to master ‘gene writing,’ launching a star-studded biotech with big ...

Yesterday

Out of jobs, a pair of early cell therapy executives went to Seoul, came back with a new company, $70M and a plan to ...

Last week

Yale spinout re-engineers an immunotherapy GSK, others once abandoned

Last week

Deals

John Reed brings NK cells into Sanofi's CD38 rivalry with J&J — and offers thumbs up for Kiadis' new focus

23 hours ago

Takeda’s post-merger deals continue as OTC subsidiary is prepared for sale

Yesterday

Investors give ailing Unum a lease on life and a whole new suite of experimental cancer drugs

Yesterday

IPOs

AlloVir tests how much an antiviral biotech can reap in a pandemic stock market

Yesterday

IPO bound? Actually, Annexon was already prepped and primed to toss its S-1 to Wall Street as investors rallied

2 days ago

Freeline nabs $120M, eyes IPO as its gene therapy comes into focus

Last week

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW

Subscribe to Endpoints News

Premium storiesSee all

Which drug developers offer Trump a quick, game-changing ‘solution’ as the pandemic roars back? Eli Lilly and ...

3 days ago

Day one: The disruptor-in-chief at BridgeBio invites Brent Saunders onto the board

2 weeks ago

What’s it take to raise $700M-plus for a biotech startup? Steve Harr has some thoughts on that

3 weeks ago

Two Bay Area upstarts out to deliver on cell therapy 2.0 join forces on a quest: pursuing a Holy Grail in oncology ...

3 weeks ago

Don't missSee all

FDA bars the door — for now — against Merck’s star cancer drug after Roche beat them to the punch

21 hours ago

Trump and Navarro press again for hydroxychloroquine. Can the FDA stay independent?

Yesterday

Covid-19 roundup: Squabbles with government delay Moderna’s PhIII — reports; Novavax secures largest Warp Speed ...

Yesterday

Cellectis slammed after patient dies and FDA slaps a hold on their trial for an off-the-shelf CAR-T for multiple ...

2 days ago

Endpoints Standouts

The 20 under 40: Inside the next generation of biopharma leaders

3 months ago

Here are the 52 new drugs approved by the FDA in 2019. Who won? Who lost? And who just survived to 2020?

6 months ago

Special report: Twenty extraordinary women in biopharma R&D who worked their way to the top

8 months ago

[Video] Celebrating trial failures, changing the culture and allying with California dreamers: R&D chief Hal Barron ...

8 months ago

Peer review See all

Jul

2

Novavax snags Ben Machielse for CMC and promotes a trio of staffers; Marty Duvall lands another CEO post at ...

Jun

26

Inovio adds two to the leadership team; Adrian Woolfson is out at Sangamo

Jun

19

Boehringer Ingelheim nabs new US president and CEO; AstraZeneca vet hops aboard Novavax as CMO

Jun

12

'Rising star' CEO recounts path from pre-med to breakthrough meds; Dendreon taps Big Pharma vet Jason O'Neill as CEO

Jun

5

David Chang steps up to CEO spot at WuXi's cell and gene therapy CDMO; David Meline is the new CFO at Moderna

R&D channel feed

Yesterday

GSK sets the stage for a toe-to-toe market showdown with Gilead's HIV champion Truvada

ViiV Healthcare and majority owner GlaxoSmithKline have cleared another important hurdle on a long-running quest to challenge Gilead’s dominance in preventative HIV treatments. The final ...

READ MORE

Second PhIII study for Idorsia's sleep drug returns positive results, but also raises new questions

2 days ago

UPDATED: Immunomedics spells out PFS benefit of Trodelvy in mTNBC, hunting a full OK just weeks after accelerated ...

2 days ago

latest in R&D

UPDATED: ObsEva’s second uterine fibroids PhIII comes through, sending some investors to the hills

2 days ago

Bellus hit with a setback as its PhII chronic cough drug flops on all 4 doses -- shares cremated on Wall Street

2 days ago

Development partners at MEI, Helsinn dump a high-risk PhIII AML study after concluding it would fail survival goal

6 days ago

Ionis, leading MS researcher throw antisense at a new type of brain cells

Last week

Pfizer shares surge on positive impact of their mRNA Covid-19 vaccine — partnered with BioNTech — in an early-stage study

Last week

see latest stories

Pharma channel feed

2 days ago

A little biotech slaps back at a 'criminal' short attack, vowing to pursue a prosecution of their case

As short attacks go, Biotech Research Partners’ assault on Applied Therapeutics' “cherry picked” data and a variety of so-called red flags didn’t cause a whole lot of damage. Ahead of the ...

READ MORE

Novartis pays $678M for kickback scheme as Vas Narasimhan tries to distance pharma giant from shady behavior

6 days ago

Novartis loses biosimilar appeal as court upholds a 31-year monopoly by Amgen's Enbrel

6 days ago

latest in Pharma

An experienced biotech is stitched together from transpacific parts, with 265 staffers and a focus on ‘new biology’

Last week

New standard of care? FDA hands Pfizer, Merck KGaA an OK for Bavencio in bladder cancer

Last week

On a roll, Merck blazes through a new segment of the biomarker trail

Last week

Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra

Last week

Gilead opts for $3,120 US insurer price for Covid-19 drug remdesivir — but some say it should be free

Last week

see latest stories

Coronavirus channel feed

22 hours ago

Covid-19 roundup: Moderna sticks to July for its Phase III as rumors swirl; Following US lead, EU buys up Covid-19 treatments

The Phase III might be delayed from its original early July goal, but Moderna says it will still kick off the pivotal study for what could ultimately be the first Covid-19 vaccine before ...

READ MORE

Covid-19 roundup: Teamed up with NIH, Regeneron launches PhIII prevention trial for antibody cocktail

2 days ago

Covid-19 has roiled clinical trial plans around the world, raising concerns over the industry’s future on new drug ...

Last week

latest in Coronavirus

Covid-19 roundup: Vaccines will need to beat placebo by 50% to qualify for FDA OK; UK trial drops Kaletra

Last week

WHO ACT-Accelerator prioritizes global vaccine approach

Last week

Covid-19 roundup: Temasek leads a $250M raise for BioNTech as first Covid-19 mRNA vaccine data looms; China's military OKs first use of coronavirus vaccine

Last week

Covid-19 roundup: Moderna enlists Catalent as manufacturing partner, securing fill-finish capacity for the first 100M doses

Last week

Covid-19 roundup: Anthony Fauci, Stephen Hahn testify in Congress; China's Sinopharm speeds into PhIII vaccine trial

2 weeks ago

see latest stories